Xopenex levalbuterol beta-2 adrenergic receptor agonist regulatory update

SEPR received a letter from the FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) regarding reports from health care professionals that a SEPR sales representative made oral sta...